Abstract
Copeptin is the C-terminal end of pre-provasopressin released equimolar to vasopressin into circulation and recently discussed as promising cardiovascular biomarker amendatory to established markers such as troponins. Vasopressin is a cytokine synthesized in the hypothalamus. A direct release of copeptin from the heart into the circulation is implied by data from a rat model showing a cardiac origin in hearts put under cardiovascular wall stress. Therefore, evaluation of a potential release of copeptin from the human heart in acute myocardial infarction (AMI) has been done.
Highlights
Elevation of AVP and copeptin can be observed in a variety of pathophysiological conditions e.g. type 2 diabetes[7,8], pneumonia[9], acute pancreatitis[10,11], sepsis[12,13] and cardiac stress and injury[14,15,16,17]
To determine whether the heart contributes to the release of copeptin into the bloodstream in humans, we measured copeptin levels in patients suffering an acute myocardial infarction (AMI) and in patients without AMI
Levels of cardiac troponin T (cTnT), as established biomarker representing myocardial ischemia, as well as copeptin were determined in samples from the aorta (AO) and the coronary venous sinus (CVS) in patients with (n = 15) and without (n = 14) the diagnosis AMI
Summary
Elevation of AVP and copeptin can be observed in a variety of pathophysiological conditions e.g. type 2 diabetes[7,8], pneumonia[9], acute pancreatitis[10,11], sepsis[12,13] and cardiac stress and injury[14,15,16,17]. Besides the established biomarkers for cardiac injury like cardiac troponins, copeptin levels might provide additional information regarding circulatory stress levels and hemodynamic instability. Copeptin has shown to provide amendatory diagnostic information for early discrimination of e.g. acute myocardial infraction (AMI) in combination with cardiac troponins in most published studies[14,15,16,17]. This study implies a potential release of copeptin from the heart into the circulation. We analyzed a potential release from the heart by measuring the concentration of copeptin using a transcoronary gradient model (TCG) in patients with AMI
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
